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Pauliina Nousiainen1, Laura Merras-Salmio2, Kristiina Aalto2 and Kaija-Leena Kolho2*Abstract
Background: The use of complementary alternative medicine (CAM) is potentially prevalent among paediatric
patients with chronic diseases but with variable rates among different age groups, diseases and countries. There are
no recent reports on CAM use among paediatric patients with inflammatory bowel disease (IBD) and juvenile
idiopathic arthritis (JIA) in Europe. We hypothesized that CAM use associates with a more severe disease in
paediatric IBD and JIA.
Methods: A cross-sectional questionnaire study among adolescent outpatients with IBD and JIA addressing the
frequency and type of CAM use during the past year. The patients were recruited at the Children’s Hospital,
University of Helsinki, Finland.
Results: Of the 147 respondents, 97 had IBD (Crohn’s disease: n = 46; median age 15.5, disease duration 3.4 years)
and 50 had JIA (median age 13.8, disease duration 6.9 years). During the past 12 months, 48% regularly used CAM
while 81% reported occasional CAM use. Compared to patients with JIA, the use of CAM in IBD patients tended to
be more frequent. The most commonly used CAM included probiotics, multivitamins, and mineral and trace
element supplements. Self-imposed dietary restrictions were common, involving 27.6% of the non-CAM users but
64.8% of all CAM users. Disease activity was associated with CAM use in JIA but not in IBD.
Conclusions: CAM use is frequent among adolescents with IBD and JIA and associates with self-imposed dietary
restrictions. Reassuringly, adherence to disease modifying drugs is good in young CAM users. In JIA, patients with
active disease used more frequently CAM than patients with inactive disease. As CAM use is frequent, physicians
should familiarise themselves with the basic concepts of CAM. The potential pharmacological interaction or the
toxicity of certain CAM products warrants awareness and hence physicians should actively ask their patients about
CAM use.
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Inflammatory bowel disease (IBD) incidence is on the
rise, especially in Western countries [1]. In Finland, the
incidence of paediatric IBD is high, approximating 15/
100 000 in 2003, with an estimated annual increase of
6.5% [2]. IBD is typically diagnosed in late adolescence
or early adulthood and often leads to an impairment
of the quality of life [3,4]. Adolescents may suffer from* Correspondence: kaija-leena.kolho@helsinki.fi
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article, unless otherwise stated.emotional and social problems and have impaired com-
petence compared to their peers [5,6]. Active IBD may
also impair cognitive functions [7]. With Crohn’s disease
(CD) in particular, adolescents also face the risk of
delayed growth and delayed puberty. Since paediatric pa-
tients often suffer from more extensive and aggressive
forms of the disease, the need for corticosteroids, immu-
nosuppressants and biologics are frequently indicated
[8,9]. However, complete remission is infrequent and
most patients experience a relapsing disease course.
The incidence of juvenile idiopathic arthritis (JIA),
another common chronic autoimmune disease intral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in contrast to IBD, no increase in the number of cases
has been observed in recent years [10]. One third of the
JIA patients have initially oligoarticular disease without
disease progression and a remarkable degree of disability
[11]. One-third of JIA patients have polyarticular disease
with a high risk of disease progression and disability
[12]. The remaining one-third of the patients belongs to
the extended oligoarticular, spodylarthropathy or sys-
temic onset JIA group, with a potentially complicated
course of disease. Similar to IBD, most patients have re-
peated relapses [13]. The first-line medications used for
JIA are non-steroidal anti-inflammatory drugs (NSAID)
and intra-articular corticoid injections, followed by dis-
ease modifying drugs (DMARD), and in the most severe
cases, new biological drugs [14].
The use of complementary and alternative medicine
(CAM) may be frequent among patients with chronic dis-
eases, such as IBD and JIA [15,16], but no recent studies
on paediatric and adolescent CAM use have been con-
ducted in the Scandinavian countries and the number of
studies worldwide is limited. The concept of CAM in-
cludes various medical practices and products that are not
commonly considered to be part of conventional medicine.
CAM practices are often grouped into five categories: 1)
whole medical systems (e.g. homeopathic medicine,
acupuncture), 2) mind-body medicine (e.g. meditation,
mental healing, hypnosis), 3) biologically-based practices
(e.g. herbal products, dietary supplements), 4) manipulative
and body-based practices (e.g. chiropractic, osteopathy,
massage) and 5) energy medicine (e.g. light therapy, reiki,
healing touch) [17,18]. Using CAM therapies may be bene-
ficial, but such therapies can also interact with the conven-
tional medications. Most alarmingly, some products may
have serious adverse effects resulting in, for example, a
deterioration of the liver function [19].
In paediatric IBD, the frequency of CAM use among pa-
tients varies from 6.7% in Canada [20] to estimates of 37%
in Scotland [21], 50% in the USA [22-24] and 72% in
Australia [25]. In the Nordic countries, an adult IBD study
reported that only 7.5% of patients regularly use CAM
[15]. With respect to JIA, the frequency of CAM use
seems comparable to IBD, at 34–92% [16,26-29]. However,
most paediatric studies have only included a limited num-
ber of patients and the findings have rarely been related to
disease activity. Also, the definition of CAM varies, with
some studies including the use of specific diets or regular
multivitamin tablets as forms of CAM.
Since CAM use is potentially prevalent among patients
with chronic diseases, we assessed the frequency of
CAM use in Finnish adolescent IBD and JIA popula-
tions. We hypothesized that CAM use associates with
a more severe disease in paediatric IBD and JIA
populations.Methods
Questionnaire
The use of CAM was assessed using a questionnaire that
included 43 items (Additional file 1). The comprehen-
siveness of the questions was pre-tested in a group of 10
adolescents with no chronic disease. We then handed
out the questionnaire to consecutive patients with IBD
and JIA, aged 12 to 18 years, during routine follow-up
visits at the outpatient clinic of Children’s Hospital, Uni-
versity of Helsinki, a tertiary care hospital, between June
2011 and June 2012. The patients were advised to fill in
the form at home together with the primary caregiver
and to return it in a prepaid envelope. An additional 100
questionnaires with return envelopes were mailed to pa-
tients who did not have scheduled visits during the study
period (50 IBD and 50 JIA patients; mailing 1 June
2012). No reminders were sent. During clinical visits,
the clinical disease activity was scored according to the
physicians’ global assessment (PGA (4)). IBD patients
also received a questionnaire assessing disease activity
and general wellbeing and JIA patients either completed
the Child Health Assessment Questionnaire (CHAQ)
(scores 0–3 (29)) and assessed their general wellbeing
using a visual analogue scale (VAS, scores 0–100) or else
the disease activity was assessed using the modified
JADAS10 without the patient’s VAS [30]. All of the ques-
tionnaires were coded and analysed anonymously. Exclu-
sion criteria included hospitalized patients.
The questionnaire included items pertaining to the use
of products containing vitamins, trace elements, probio-
tics, energy drinks, recovery products and specific nutri-
tional products for athletes during the past 12 months.
Twenty-eight specific questions requested information
about whether or not the patient had used a certain
group of products or therapy; if they answered “yes”,
they were asked a specific follow-up question about the
type of product/therapy and how much and how often
they had used it. A product used three times a week or
more was often considered to fit a pattern of regular
use. An open-ended question asked about the use of any
other product or therapy not listed. Also, data on the
use of special diets or the avoidance of any food ingredi-
ents and information on socioeconomic factors (such as
family size and housing details) were requested. Further-
more, questions on the use of the medications to treat
IBD, JIA or other possible concomitant disease as well
as any antibiotics were also included. Adherence to
disease-modifying medication was estimated by asking
patients how often they forgot to intake the medication
prescribed by the physician (monthly or less/weekly/
daily). We abstracted this information from the patient
charts, the specific data on prescribed IBD/JIA medica-
tions, including steroids, immunosuppressive or immu-
nomodulative agents, TNFα-blockers or other biologics,
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salazopyrine, or hydroxychloroquine) at the time that
the patients took part in the study.
In this study, CAM use was defined based on the
study by Hilsden et al. [18]. Vitamin D substitution was
not considered to be a part of CAM, since Finnish na-
tional guidelines (as established by the National Institute
of Health and Welfare) support the daily use of 7.5 to 10
μg/day for all children less than 18 years of age. Like-
wise, since the use of iron products and calcium supple-
ments is usually by prescription, and although data were
requested on their use, these products were not consid-
ered to be a part of CAM either. Here, we listed probio-
tics as CAM, even though their possible benefit in IBD
is still a point of discussion. While dietary modifications
were not treated as CAM in this study, they are dis-
cussed separately.
For the group of patients recruited during routine
clinical visits, their vitamin D serum levels (D-25-OH-
vitamin) and blood count were assessed in the clinical
laboratory.
Ethical considerations
The ethical committee of Helsinki University Hospital
approved the study protocol. The patients and/or their
guardians who were recruited during clinical visits and
agreed to blood sampling signed an informed consent
form.Table 1 Background characteristics of the adolescent patients
idiopathic arthritis (JIA)
IBD
No. of respondents 97
% of all respondents 66%
(% of recruited patients) (76%*)
Recruited during 74
Clinical visits (% of respondents) (76%)
Recruited by mail 24
(% of respondents) (24%)
Age, median (IQR) 15.5*
(13.7-16.7)
Gender, male 51
(%) (53%)
Disease duration 3.4*
(years), median (IQR) (1.3-5.4)
Disease subtype Crohn’s: n = 46
Ulcerative colitis: n = 41
Unclassified colitis: n = 10
IQR = interquartile range; n.a. = not applicable.
*p < 0.001 between IBD and JIA groups.
**including oligoarthritis extended: n = 7.Statistical analyses
Data are presented either as means (± standard devi-
ation) or as medians (interquartile range), as appropriate
for the distribution normality. Correlations between in-
dividual continuous parameters were sought using the
Spearman correlation and between dichotomous param-
eters using the Kruskall-Wallis or Mann Whitney U test,
when appropriate. Fisher’s exact two-sided test was used
for comparisons related to frequencies. GraphPad Prism®
Version 5.0c was used for the analyses. The statistical
significance was set as p < 0.05.
Results
The background data for the 147 respondents is shown
in Table 1. The total response rate of IBD patients com-
pared to JIA patients was significantly higher (76% ver-
sus 51%, p = 0.0001). Of the patients recruited during
in-house visits, 8.8% refused to participate in the study
(IBD: n = 5, male: n = 2; JIA: n = 8, male: n = 4). The re-
sponse rates for the IBD and JIA groups who received
the questionnaire by mail were 46% and 20%, respect-
ively, comprising in total 34 respondents from the
“mailed” group. There were no major differences in the
characteristics between the groups recruited as a result
of their clinical visit or by mail, so the data have been
pooled collectively. The questionnaires were generally
completed in full, with missing items on average being
less than one per questionnaire.with inflammatory bowel disease (IBD) and juvenile
JIA Total
50 147
34% n.a.
(51%*) (65%)
40 113
(80%) (77%)
10 34
(20%) (23%)
13.8* 14.7
(12.7-14.9) (13.0-16.2)
17 68
(34%) (46%)
6.9* 3.8
(2.7-10.1) (1.6-7.6)
Oligoarthritis: n = 18
Polyarthritis: n = 25**
Enthesitis related: n = 4
Psoriasis related: n = 3
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shorter disease duration compared to the JIA patients
(Table 1). We performed a dropout analysis to assess
possible selection bias (differences between respondents
and non-respondents). Those patients who returned the
questionnaire were comparable by age and gender with
those who did not return it (IBD non-respondents: n =
27, median age 15.8, male: n = 15; JIA non-respondents:
n = 41, median age 14.8, male: n = 15), and based on the
chart review, there were no major differences in disease
characteristics (data not shown).
During the past year, 48% of all patients regularly used
CAM (54% and 38% of IBD and JIA patients, respect-
ively; p = 0.08; Table 2). However, the proportion of all
patients who have tried at least once CAM or who have
used it irregularly (less than three times a week) was
81%. The most frequently used CAM were probiotics,
multivitamin products, and mineral and trace element
supplements (Table 2). The mind-body medicine and
body-based practices included acupuncture, reflexology,
and massage.
Of all CAM users, 64.8% consumed special diets, which
was significantly higher than for the non-users (27.6%,
p < 0.0001). When those patients on a lactose-free diet
were excluded (since the diet may be considered to reflect
genetic hypolactasia in the study population (31), the re-
spective figures were 48.5% and 13.1% (p < 0.001). The
most commonly consumed diets included non-dairy or
gluten-free diets and the avoidance of fruits and vegeta-
bles, with the frequencies being comparable between
IBD and JIA patients (Table 3). CAM users with self-
imposed dietary restrictions more often used a combin-
ation of several CAM products than those on regular
diets (p < 0.0016).
The type of medication used for disease control did
not associate with CAM use. Those patients with a mod-
erate to severe disease treated with biologics, corticoidsTable 2 The use of products considered complementary alter
inflammatory bowel disease (IBD, n = 97) and juvenile idiopa
No. of patients using CAM (percentage of respondents with the given d
Probiotics
Multivitamin products
Minerals and trace elements*
Omega-3 and −6 products
Supplementary nutrition products for athletes
Mind-body medicine
Body-based practices and energy medicine
The differences between the IBD and JIA groups are not statistically significant.
*iron and calcium substitutions excluded.or immunosuppressants used CAM in a comparable
manner as the other patients. Also, the proportion of pa-
tients reporting poor compliance to the prescribed medi-
cation was similar between CAM users and non-users,
and comparable between the IBD (19%, with 18/97
reporting weekly non-compliance) and JIA groups (26%,
with 13/50 reporting weekly or daily non-compliance, p
> 0.05, Fisher’s exact two-sided test). There were no sig-
nificant gender differences (55% of all CAM users were
boys) or differences related to the environment or family
(place of residence, family size, domestic animals or pets,
smoking) associated with CAM use (data not shown).
We found no association between disease duration and
CAM use.
We found that among IBD patients, CAM use was
not related to disease activity (Table 4). The disease was
clinically active in 18% of the IBD patients, with the
others displaying clinical remission or only mild activity.
Within the group with the most active disease, 59% of
the patients reported CAM use as opposed to 44% of
the patients with the mildest disease. For JIA patients,
the overall disease activity was fairly low and only 24%
had JADAS10 scores indicating active disease (high
score 3: n = 1, score 2: n = 3, score 1: n = 8; all of the
other patients had a score of 0 [30]. Compared to those
with minor symptoms, CAM use among JIA patients
with active disease was more frequent (p = 0.038,
Table 4).
We found no difference in haemoglobin levels when it
came to CAM use (median levels 128 g/l and 125 g/l in
users and non-users, respectively). Likewise, D-25-OH
levels in serum were comparable between CAM users
and non-users (median 77 nmol/l IQR 56–97 and
75 nmol/l, IQR 56–88, respectively). Neither were there
significant differences when these parameters were com-
pared between the IBD and JIA groups (data not
shown).native medicine (CAM) among adolescents with
thic arthritis (JIA, n = 50)
IBD patients using CAM JIA patients using CAM
iagnosis) 52 (54%) 19 (38%)
The proportions of the products used that are
considered CAM (among CAM users)
62% 58%
54% 42%
37% 21%
23% 37%
12% 0%
7.7% 0%
3.8% 5.3%
Table 3 Diet restrictions related to the use of complementary alternative medicine (CAM) in adolescents with
inflammatory bowel disease (IBD: n = 97) and juvenile idiopathic arthritis (JIA: n = 50)
IBD patients using a
special diet
JIA patients using a
special diet
Total study group
(n = 147)
No. of patients with a special diet (percentage of total
respondents)
53 (54.6%)* 14 (28%)* 67 (45.6%)
CAM
users
Non-
users
CAM
users
Non-
users
CAM
users
Non-
users
n = 52 n = 45 n = 19 n = 31 n = 71 n = 76
No. of patients with special diets 36 (69.2%) 17 (37.8%) 10 (52.6%) 4 (12.9%) 46 (64.8%)** 21 (27.6%)**
Non-dairy (% of the patients on a special diet) 30.6% 23.5% 10% 25% 26% 23.8%
Lactose-free (% of the patients on a special diet) 22.2% 47.1% 40% 75% 26% 52.4%
Gluten-free (% of the patients on a special diet) 19.4% 11.8% 10% 0% 17.4% 9.5%
Avoidance of fruits/vegetables (% of the patients on a special diet) 27.8% 17.6% 40% 0% 37% 14.3%
*difference between IBD and JIA patients: p < 0.002; **difference between CAM users and non-users: p < 0.0001.
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This cross-sectional questionnaire study assessed CAM
use in adolescent IBD and JIA patients. We found that
CAM use was frequent. During the preceding 12 months,
almost every other patient had regularly used CAM
while the proportion of patients reporting at least occa-
sional CAM use was 81%. For IBD patients, the use of
CAM seemed more frequent than for JIA patients. Un-
expectedly, dietary restrictions were common and almost
two-thirds of all CAM users reported that they were
on special diets. Disease activity did not associate with
CAM use in IBD patients, whereas JIA patients with
more active disease used CAM more frequently. How-
ever, the small number of JIA patients may bias the re-
sults. Reassuringly, compliance with disease-modifying
drugs was not affected by CAM use.
CAM remains a field of uncertainty for many practi-
tioners [18]. It is not easy to define CAM and the defini-
tions vary between countries and cultures: in Asian
countries, acupuncture is usually not considered a form
of CAM, as it would be, for instance, in the Scandi-
navian countries. As fish oils and probiotics are widely
used, some researchers no longer consider them CAM.
We included probiotics within the concept of CAM,
with them being the most frequently used form of CAM
followed by multivitamin products, mineral and trace
element supplements, and omega-3 and −6 products.Table 4 Disease activity and the use of complementary altern
bowel disease (IBD) and juvenile idiopathic arthritis (JIA)
IBD (n = 95)*
CAM users
n = 45
Inactive or mild disease activity 25
Moderate to severe disease activity 22
*data missing: n = 2; **CAM significantly more frequent among patients with activeOn the other hand, we did not consider vitamin D sub-
stitution or the use of iron or calcium supplementation
as CAM. Here, the patients’ D-25-OH and haemoglobin
levels were well within the given cut-off for normal
values regardless of whether or not they reported using
CAM.
Chronic disease has been reported to associate with
CAM use in children [31], but research on paediatric pa-
tients is limited. In North America, CAM use among
both paediatric IBD [22-24] and JIA patients [16,26-29]
is considerably more common than among healthy chil-
dren ([32]. The most commonly reported forms of CAM
use among children with IBD included proiotics, fish
oils, herbs, dietary modifications and megavitamin ther-
apy, all of which are well in line with our findings. Here,
the regular use of CAM was within the range reported
in earlier studies, but we found that a higher proportion
of the patients (81%) use CAM at least occasionally.
Unexpectedly, 65% of CAM users reported various
dietary modifications, including a gluten-free diet and
the avoidance of fruit and vegetables. A Scottish study
found that 28% of patients had adopted a dairy-free diet
as a dietary modification, which corresponds to the pro-
portion of dietary modifications reported by non-CAM
users in our study [21]. Perhaps surprisingly, JIA patients
also reported following special diets, with there being
no significant differences compared to the IBD patients.ative medicine (CAM) in adolescents with inflammatory
JIA (n = 50)**
Non-users CAM users Non-users
n = 50 n = 19 n = 31
28 11 27
22 8 4
JIA (p < 0.05).
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those with self-imposed restricted diets also used mul-
tiple types of CAM significantly more often. This associ-
ation most likely reflects the attitudes of the caregivers
to CAM, but it still warrants a thorough history taking
and nutritional assessment when encountered. Manipu-
lative and mind-body-based therapies, such as chiroprac-
tic and relaxation techniques and homeopathy, have
previously been popular among JIA patients [26-29,33].
Here, the use of mind-body and manipulative CAM was
rare. Furthermore, there was no significant difference in
the reported CAM use between JIA and IBD patients, al-
though the latter group of patients seemed to use CAM
more frequently.
For JIA patients, longer disease duration has been associ-
ated with CAM use [16]. Interestingly, we found no signifi-
cant difference in disease duration with respect to CAM
use. The type of medication had no association with CAM
use and, for example, those on immunosuppression and/or
biologics did not report using CAM more frequently, un-
like what we had originally hypothesized.
Indicators identified to predict CAM use include a de-
sire for better disease control and the perceived helpful-
ness of CAM [28,34]. The conventional medications for
IBD and JIA patients alleviate symptoms but are often
unsatisfactory or have significant side effects. Many
drugs are poorly studied in paediatric populations [8],
which may evoke concern. Reassuringly, CAM use does
not seem to associate with overall reduced adherence to
medical therapy [35]. Caregivers reported that the side
effects from prescribed medicine, the disappointment
with their effects [22] and the wish to relieve their child’s
pain and to improve his/her overall wellbeing [27,28]
were the major reasons for CAM use. The reasons for
the use of CAM were not questioned in our study. Here,
according to self-reports, the adherence to conventional
medication was nevertheless excellent in more than 70%
of the IBD and JIA patients. Thus, we found no signifi-
cant reduction of treatment compliance among adoles-
cent IBD/JIA patients using CAM.
Many patients or parents may be reluctant to tell their
physician about CAM use, possibly thinking that it is not
relevant [18,27,36] but this aspect was not assessed in the
current study. Furthermore, patients tend to believe that
CAM therapies are safer and less toxic than conventional
medication, which is not always true. Alarming reports
show severe liver failure resulting in the need for trans-
plantation after use of, for example, certain herbal products
[19,37]. When taking care of paediatric patients with
chronic diseases, every effort should be made to make the
families feel confident and willing to share information re-
garding CAM use. In most cases, the use of CAM may not
be especially harmful, but it may be unnecessary for the pa-
tients and this also needs to be discussed with the families.This study assessed for the first time CAM use simul-
taneously among adolescents with IBD or JIA. The
returned questionnaires were generally completed in full.
The results were related to disease activity and medica-
tion adherence via chart review. The study was mainly
conducted by the personnel taking care of the IBD pa-
tients, which likely diminished the interest of JIA pa-
tients to participate, especially those who received the
questionnaires by mail. We did not sent out reminders,
as the initial mailing of the questionnaires was done at
the end of the school term. The overall response rate
was satisfactory, but the smaller proportion of JIA re-
spondents was unexpected. The IBD/JIA population,
however, is likely to be representative of the respective
patient populations, as the comprehensive care for these
patients is provided at our tertiary level unit and similar
services are not available elsewhere.
Conclusions
Physicians should familiarise themselves with the basic
concepts of CAM and actively ask their patients about
their CAM use, with it being frequent among adolescent
IBD and JIA patients. Regular use of CAM associates
with dietary restrictions to be detected at medical
follow-ups. Reassuringly, adherence to disease modifying
drugs is good in young CAM users, but potential
pharmacological interaction or the toxicity of certain
CAM products warrants greater awareness.
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